Hong Kong stocks started “booming” in May! The Hang Seng Index reclaimed the 18,000 mark, and in April, Demon Stock added another 30% assist
On May 2, Hong Kong stocks ushered in the first trading day of May, and the three major stock indexes continued their major counterattack!
Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 26%, leading the innovative drug concept, ASCO catalyzes market conditions, institutions are optimistic about policy+health insurance marginal improvement
Zhitong Finance App learned that innovative drug concept stocks showed strong performance. As of press release, Cornerstone Pharmaceutical-B (02616) rose 26.14% to HK$1.11; Cansino Biotech (06185) rose 16.91% to HK$20.95; Gacos-B (01167) rose 14.2% to HK$1.93; Nuocheng Jianhua (09969) rose 12.31% to HK$5.2; Rongchang Biotech (09995) rose 10.2% to HK$30.8. According to the news, the research title of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was on April 25
Changes in Hong Kong stocks 丨 Biotech stocks continue to strengthen, the cornerstone pharmaceutical industry rises nearly 23%
Glonghui, May 2 | Cornerstone Pharmaceuticals rose nearly 23%, Cansino Biotech rose nearly 14%, Lepu Biotech rose more than 10%, and Pharmaceutical Kangde rose nearly 8.5%.
Hong Kong biotechnology stocks continued to strengthen. Cornerstone Pharmaceuticals rose nearly 23%, Gacos rose more than 14%, Cansino Biotech rose nearly 14%, Lepu Biotech rose more than 10%, and Pharmacom Kangde rose nearly 8.5%.
Hong Kong biotechnology stocks continued to strengthen. Cornerstone Pharmaceuticals rose nearly 23%, Gacos rose more than 14%, Cansino Biotech rose nearly 14%, Lepu Biotech rose more than 10%, and Pharmacom Kangde rose nearly 8.5%.
The Hang Seng Index rose more than 2%, the Hang Seng Technology Index rose 3.7%, Hong Kong biotech stocks rose higher, Cansino Biotech rose more than 10%, and Rongchang Biotech rose more than 6%.
The Hang Seng Index rose more than 2%, the Hang Seng Technology Index rose 3.7%, Hong Kong biotech stocks rose higher, Cansino Biotech rose more than 10%, and Rongchang Biotech rose more than 6%.
Changes in Hong Kong stocks | Cansino Biotech fell more than 5%, and its loss increased to 170 million yuan in the first quarter. It plans to sign a product transfer and technology licensing agreement with Shanghai Pharmaceutical Cansino
Cansino Biotech (06185) fell by more than 5%. As of press release, it was down 5.11% to HK$17.84, with a turnover of HK$15.417,300.
Cansino Biotech (06185) plans to transfer AD5-eBoV and its global commercialization rights to the drug Cansino
Cansino Biotech (06185) announced that the company plans to sign a “Product Transfer and Technology License Agreement” with Shanghai Pharmaceutical Cansino, approximately...
康希諾生物:截至2024年3月31日止三個月的第一季度報告
Express News | Cansino: Plans to sign a product transfer and technology licensing agreement with Shanghai Pharmaceutical Cansino
Express News | Cansino: Q1 revenue of 114 million yuan, up 13.65% year on year; Q1 net loss of 170 million yuan.
Changes in Hong Kong stocks | Cansino Biotech (06185) is now up more than 4% Hib vaccine clinical trial approved, PBPV clinical trial has achieved positive initial results
The Zhitong Finance App learned that Cansino Biotech (06185) is now up more than 4%, with a cumulative increase of more than 18% during the month. As of press release, it rose 4.1% to HK$18.8, with a turnover of HK$17.022,600. According to the news, Cansino Biotech recently announced that the freeze-dried Haemophilus influenzae type b (Hib vaccine) conjugate vaccine (Hib vaccine) developed by the company has been approved by the China National Drug Administration and can carry out related clinical trials. Haemophilus influenzae is a gram-negative bacillus and is one of the most important pathogens of acute lower respiratory infections in children. Cansino Biotech also previously announced the recombinant pneumonia developed by the company
康希諾生物:2023年度報告
Changes in Hong Kong stocks | Pharmaceutical stocks strengthened in the afternoon, and the innovative drug policy showed a positive trend, and the sector is expected to continue to warm up after the second quarter
Pharmaceutical stocks strengthened in the afternoon. As of press release, Laikai Pharmaceutical-B (02105) rose 13.67% to HK$6.07; Conoa-B (02162) rose 13.21% to HK$33; and Pharmaceuticals (02268) rose 7.52% to HK$20.15.
Changes in Hong Kong stocks | Cansino Biotech (06185) once rose nearly 6% and freeze-dried Haemophilus influenzae type b conjugate vaccine was approved for clinical trials
At one point, Cansino Biotech (06185) rose nearly 6%. As of press release, it rose 4.69% to HK$18.32, with a turnover of HK$8.3079 million.
The majority of Hong Kong pharmaceutical stocks rose, and Pharmacovigilance rose more than 8%
Glonghui, April 23 | Pharmacovigilance increased by more than 8%, Cansino Biotech increased by more than 5%, and Pharmaceutical Kangde rose nearly 3%.
Featured announcements | Zijin Mining's Q1 net profit increased 15% year over year; Bubble Mart's overseas revenue increased by more than 240% in the first quarter
China Mobile's Q1 net profit increased 5.5% year over year to 29.6 billion yuan; Chabaidao's IPO was priced at HK$17.50 per share, with a net raise of HK$2,463 billion.
Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine
Cansino Biologics (HKG:6185) received approval from the National Medical Products Administration of China to begin clinical trials for its Haemophilus influenzae Type B (Hib) Conjugate Vaccine, a Mond
Cansino Biotech (06185.HK): Freeze-dried Haemophilus influenzae type b conjugate vaccine approved for clinical trials
Gelonghui, April 22丨Cansino Biotech (06185.HK) announced that the freeze-dried Haemophilus influenzae type b (Hib) conjugate vaccine developed by the company has been approved by the China National Drug Administration and can carry out relevant clinical trials. Haemophilus influenzae is a gram-negative bacillus and is one of the most common pathogens of acute lower respiratory infections in children. It is divided into capsular type and non-perpendicular type, both of which can cause infection. Non-capsular strains often cause diseases such as otitis media and sinusitis. It is mainly caused by nasopharyngeal colonizing bacteria spreading to nearby sites; infections secondary to bloodstream attacks are usually caused by capsular strains. There is a capsular
Cansino (688185.SH): Hib vaccine clinical trial approved
Cansino (688185.SH) issued an announcement. The company recently received approval and issuance from the State Drug Administration...
Express News | Cansino: Freeze-dried Haemophilus influenzae type b conjugate vaccine obtains drug clinical trial approval notice
No Data